Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Tucci, Marcello;Tortora, Giampaolo;Scagliotti, Giorgio Vittorio;
2017-01-01

2017
390
10109
2266
2277
http://www.journals.elsevier.com/the-lancet/
Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Medicine (all)
Petrylak, Daniel; de Wit, Ronald; Chi, Kim Nguyen; Drakaki, Alexandra; Sternberg, Cora N; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed; Fléc...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1693667
Citazioni
  • ???jsp.display-item.citation.pmc??? 64
  • Scopus 141
  • ???jsp.display-item.citation.isi??? 131
social impact